The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•5 May 2026•

1 min read

IDEAYA Biosciences Reports Wider-Than-Expected Q1 Loss

Key Facts

1IDEAYA Biosciences reported a quarterly loss of $1.11 per share, missing the Zacks Consensus Estimate of a loss of $1.07.

2The company's losses widened compared to a year ago when it reported a loss of $0.82 per share.

IDEAYA Biosciences reported its first-quarter financial results, posting a loss of $1.11 per share, which was deeper than the Zacks Consensus Estimate of a $1.07 loss. This performance marks a significant widening of losses compared to the same period last year, when the company reported a loss of $0.82 per share. The biotech firm also missed revenue estimates, highlighting increased financial pressure on its development operations. Investors typically view such misses in both earnings and revenue as a bearish signal for mid-cap biotechnology stocks. The widening year-over-year loss reflects the ongoing challenges of balancing high research and development costs with revenue generation. Consequently, the stock may face downward pressure as the market reacts to these disappointing quarterly figures.

Version History

2 additional sources confirmed this story